



# Pre-operative partial breast irradiation: revolutionizing radiation treatment for women with early stage breast cancer

Yun R. Li<sup>1^</sup>, Parul N. Barry<sup>2</sup>

<sup>1</sup>Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; <sup>2</sup>Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA

*Contributions:* (I) Conception and design: Both authors; (II) Administrative support: PN Barry; (III) Provision of study materials or patients: Both authors; (IV) Collection and assembly of data: YR Li; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.

*Correspondence to:* Yun R. Li, MD, PhD. Department of Radiation Oncology, University of California San Francisco, 1600 Divisadero St., Suite H1031, San Francisco, CA 94117, USA. Email: yun.li2@ucsf.edu or yunroseli@gmail.com; Parul N. Barry, MD. Department of Radiation Oncology, UPMC Hillman Cancer Center, Magee-Womens Hospital, 300 Halket Street, Pittsburgh, PA 15213, USA. Email: pnbarry@gmail.com.

**Abstract:** Partial breast irradiation (PBI) has been increasingly accepted as a suitable component of breast conservation in the management of patients with early stage breast cancer, however the majority of existing studies have focused on the use of adjuvant or intra-operative techniques. Several early stage studies have more recently shown that PBI can be safely used in the pre-operative setting. Early data show similar local control without evidence of increased toxicity or worsening cosmesis, as compared to postoperative PBI or standard whole breast irradiation. While long term data are still maturing, pre-operative accelerated PBI (PAPBI) offers a number of possible clinical advantages including reducing the treatment field and increasing the number of patients eligible for PBI, identifying biomarkers of response to radiation, and improving the rates of breast conservation and treatment compliance. This review discusses key concepts and controversies surrounding PBI as it has increasingly been adopted in the US, Canada, and Europe, and introduces the concepts and early studies of PAPBI. In addition, we summarize ongoing clinical trials investigating PAPBI, review clinical benefits and challenges associated with PAPBI versus postoperative PBI, and discuss ongoing limitations as well as next generation technologies important to the implementation of PAPBI in the management of patients with early-stage localized breast cancer.

**Keywords:** Partial breast irradiation (PBI); early stage breast cancer; radiation therapy; pre-operative radiation therapy; stereotactic body radiation therapy (SBRT)

Received: 07 November 2020; Accepted: 09 August 2021; Published: 30 December 2022.

doi: 10.21037/abs-20-133

**View this article at:** <https://dx.doi.org/10.21037/abs-20-133>

## Introduction

The management of early stage breast cancers has shifted significantly in the past decade. Thus far, this has been driven by advances in the availability and application of molecular and genomic testing to guide systemic treatment decision making. However, local therapies namely surgery and radiation therapy, remain the backbone of breast

conservation therapy. For most patients with early stage breast cancers undergoing breast conservation, adjuvant whole breast radiation therapy (WBRT) using a modestly hypofractionated treatment regimen remains the standard of care (1-3).

However, in the last few years, there have been a number of new advances made in the local management of early stage breast cancer. These are driven by and rely on the advances

<sup>^</sup> ORCID: 0000-0002-8077-4975.

in imaging, image guidance and treatment planning across the field of radiation oncology, leading to the development of novel concepts of management of early stage breast cancer including the use of accelerated partial breast irradiation (APBI). This entails the use of hypofractionated regimens similar to the hypofractionated regimens of WBRT, or the use of shorter regimens delivered over one to ten fractions. Data from the last decade has demonstrated the safe implementation of PBI as compared to WBRT in the postoperative setting. Many phase III randomized studies have largely shown that PBI is associated with good cosmetic and toxicity outcomes, without compromising local failure rates when compared to WBRT (4-7).

More recently, multiple early stage, proof-of-concept trials are investigating the use of PBI in the pre-operative setting (8-10). This review introduces the history and development of PBI and reviews the clinical benefits and challenges associated with pre-operative APBI (PAPBI) therapy. We also discuss the advent of next generation technologies such as magnetic resonance (MR) guided radiation therapy (RT) and Cyberknife in PAPBI as well as challenges that still remain facing more widespread adoption of PAPBI. A summary of several ongoing or recently accrued PAPBI and postoperative PBI studies is provided in *Table 1*.

### Definition and adaptation of APBI

APBI refers to the delivery of hyperfractionated, modestly hypofractionated, or extremely hypofractionated radiation therapy to the tumor-involved part of the breast as a part of breast conservation therapy. The concept of PBI developed from modern pathological analysis, which have shown that in most cases, even amongst patients who required localized re-excisions after lumpectomy, residual disease in the breast was typically limited to a margin of <10 mm around the lumpectomy cavity (11). Thus, in patients who underwent sufficient definitive resection, it was rationalized that postoperative RT could be reasonably limited to just the resection cavity plus a moderate margin without missing microscopic tumor.

Over the last several years, APBI has become more widely accepted and is now commonly utilized at most academic centers in the US and Canada. Most studies on APBI to date have shown promising local control rates as compared with WBRT, albeit most studies still have a comparably shorter follow up duration (5,7,12). APBI can be delivered via various techniques including brachytherapy,

both 3D conformal and intensity modulated external beam radiation therapy (EBRT), stereotactic body radiation therapy (SBRT), or intraoperative radiation therapy (IORT). Because of the significantly fewer fractions employed, higher doses per fraction are typically employed for PBI as compared to conventionally fractionated techniques, but it is delivered over a significantly smaller area. With the exception of IORT, which is delivered in a single fraction, PBI is most often delivered over the course of a short regiment of 5-10 fractions over 1-2 weeks to a total dose ranging from 15-40 Gy. As PBI is still an emerging treatment concept, studies have used variable dosing and fractionation regimens, hence resulting in a range of acceptable variations that is largely institution dependent.

### New interest in and advantages of PAPBI

Nevertheless, only a minority of women undergoing breast conservation in the US, Canada and Europe are treated with PBI. Limitations to widespread adoption have been attributed to concerns for an increased risk of local recurrence, poorer cosmesis and increased dose heterogeneity to the postoperative lumpectomy cavity, particularly in patients with larger tumors/cavities or small breast volume (13,14). These concerns persist even though multiple phase III studies have shown otherwise (4,6,15).

A theoretical advantage of using pre-operative therapy is the possibility of avoiding some of these toxicities that could be associated with postoperative therapy. Typically, a smaller volume could be treated (gross tumor versus post-operative tumor bed) and consequently, the area receiving the highest dose in PAPBI would be largely, if not completely, removed during lumpectomy. This would mitigate concerns regarding fibrosis or necrosis of the breast tissue in the treatment field.

Pre-operative radiation therapy has been shown to have advantages in the management of other solid tumors including cancers of the rectum, esophagus, and sarcomas. However, until very recently, pre-operative therapy has had a very limited role in the clinical management of localized breast cancer outside of clinical trials, being primarily reserved for patients with unresectable tumors despite neoadjuvant chemotherapy. In such cases, patients are offered the option of pre-operative radiation therapy with the goal achieving resectability at the time of surgery.

The hesitancy to use pre-operative RT is in part driven by historical data suggesting that there may be increased toxicity with pre-operative RT, even though most of these

**Table 1** Summary of ongoing and recently accrued postoperative and postoperative APBI studies

Institution (TRIAL)	Phase	APBI	Dose	Clinical Trials.gov ID	Notes	Study start date	Primary outcomes
Juravinski Cancer Center	Phase I	Pre-operative	8 Gy x5 EOD	NCT02065960	SBRT	February 2014	Feasibility
Georgetown University	Phase I-II	Adjuvant	6 Gy x5	NCT02365714	CK SBRT	February 2015	Feasibility
Laurentian University, Jewish General Hospital	Phase II	Pre-operative	21 Gy x1	NCT02212860	SBRT	March 2015	Toxicity
Georgetown University (SIGNAL TRIAL)	Multi-institutional registry trial	Adjuvant	5 fractions	NCT02457117	CK SBRT	May 2015	Local failure
Duke University	Phase II	Pre-operative	21 Gy x1	NCT02482376	SBRT	October 2015	Cosmesis
University of Texas Southwestern	Phase I	Adjuvant dose escalation	22.5-30 Gy x1	NCT02685332	SBRT	March 2016	Dose tolerance
The Netherlands Cancer Institute, Institut Gustave Roussy, Karolinska Institut, University Medical Centre Utrecht (PAPBI Trial)	Phase II	Pre-operative	4 Gy x10 or 5 Gy x6	NCT01024582	3-DCRT, IMRT	April 2010	Local failure
Maisonneuve-Rosemont Hospital (SPORT TRIAL)	Phase I	Pre-operative	15, 18, or 20 Gy x1	NCT01717261	SBRT	August 2012	Acute toxicity
University Medical Center Utrecht (ABLATIVE TRIAL)	Phase I	Pre-operative → BCS 6 months	15-20 Gy x1	NCT02316561	Partial breast IMRT	October 2014	pCR
Ohio State University	Phase I, pilot	Pre-operative	10 fractions BID for 5 days	NCT02186470	IMRT, prone	June 2015	Acute toxicity
Medical College of Wisconsin	Phase II	Pre-operative	5 fractions	NCT02728076	3-DCRT, MRI guided	May 2016	Postoperative complications
The Netherlands Cancer Institute (PAPBI-2)	Phase III	Pre vs. postoperative APBI	28.5 Gy in 5 fractions	NCT02913729	Partial breast IMRT	November 2016	Cosmesis
University Hospital, Grenoble (NeoAPBI 01)	Phase II randomized	Chemo vs. chemo + postoperative APBI	25 Gy in 10 BID fractions	NCT02806258	Partial breast 3-DCRT	March 2016	pCR

APBI, accelerated partial breast irradiation; EOD, every other day; SBRT, stereotactic body radiation therapy; CK, CyberKnife; 3-DCRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiation therapy; BCS, breast-conserving surgery; MRI, magnetic resonance imaging; pCR, pathologic complete response; BID, twice daily.

studies were conducted in the 1980s to early 2000s. Such studies utilized older radiation therapy techniques rather than modern 3D-based or intensity-modulated treatment planning technology. Many of these studies also used concurrent pre-operative chemotherapy, likely further increasing the likelihood of treatment-related toxicity and rates of subsequent surgical complications (16-18).

In fact, modern PAPBI studies have been implemented safely in a number of Phase I/II clinical studies. These trials, done comparatively or as an alternative to postoperative RT for patients with early stage breast cancer, typically included patients who fulfill the ASTRO APBI appropriate use guidelines. While the data is not yet mature, early reports from these studies do not appear to show significantly increased risk of toxicity or evidence of association with increased postoperative complications (19-21). In fact, some advocates of PAPBI find that there is in fact more uncertainty associated with postoperative RT, particularly when a boost is needed. In some institutions, cosmetic tissue rearrangement with oncoplastic reconstruction may take place following tumor resection at the time of lumpectomy, which can complicate treatment planning, lead to increased treatment volumes, and result in unnecessary toxicity (22-24). The use of pre-operative RT obviates this concern.

Another potential benefit of PAPBI is that it can increase the number of patients who are candidates for PBI as the total breast volumes irradiated in the pre-operative setting is likely significantly less as compared to the postoperative setting. This is because post-operative treatment fields must encompass the entire surgical bed, which is significantly larger in most cases than the gross tumor. Nichols *et al.* estimated that the pre-operative versus postoperative treatment volume APBI for 41 early stage breast cancer patients using pre-operative and postoperative imaging, showing that radiating the pre-operative tumor rather than the tumor bed can significantly reduce the treatment volume (19). Women with larger tumor to breast size ratio who would otherwise not have been candidates for adjuvant PBI may now be candidates for PAPBI. Given the significantly reduced treatment times with comparably or potentially better toxicity outcomes, this is beneficial both for the patient and the healthcare system at large.

Finally, a generally cited added benefit of PAPBI is treatment compliance. Surprisingly, epidemiological analysis shows that 18% of women in the US who are eligible for adjuvant RT did not receive post-lumpectomy treatment. The cause of attrition in this setting is likely multi-factorial,

but it obviously has an adverse impact on local control and survival (25). In addition to shortening the duration for RT, by moving PBI to the pre-operative setting, we may see significant improvement in treatment compliance.

### Treatment planning techniques in the era of PAPBI and SBRT

The earliest studies of PAPBI, such as a Phase II multi-institutional study in the Netherlands testing the toxicity and cosmetic outcome after 40 Gy in 10 daily fractions, did not require advanced treatment planning intensity-modulated radiation therapy (IMRT)/SBRT or the use of magnetic resonance imaging (MRI). This study permitted the use of 3-dimensional conformal radiotherapy (3-DCRT) for treatment planning, but the protocol specified increased clinical target volume (CTV) to planning tumor volume (PTV) expansion to 2.5 cm (21). Nevertheless, even with these large margins, the mean PTV to ipsilateral breast ratio was still less than 15%. Thus, there remains a significant reduction in treated breast volume as compared to WBRT (21). An interim report from Van de Leij on this study including 70 patients showed that 100% of patients had good to excellent cosmesis at 3 years with minimal treatment related and postoperative toxicity and only 2 local recurrences at a median follow up of 23 months.

More modern studies of PAPBI using advanced treatment planning have led to reduced treatment fields, which consequently also provided opportunities for dose escalation. Specifically, studies have shown that PAPBI can be done safely in as little as a single fraction. For example, Horton *et al.*, reported early results of a single institutional Phase I dose-finding study of single fraction PAPBI (20). This study included a total of 17 patients with T1 disease greater than 1 cm from the skin surface and used MRI for planning. Prescription was to 15 Gy  $\times$  1 using IMRT. While median follow up is only 23 months, cosmesis was rated as good or excellent in all patients without any evidence of early recurrence. While the use of MRI in treatment planning is fairly novel, breast MRI has become increasingly recognized as important in pre-surgical staging and treatment response assessment for patients with breast cancer.

Subsequently, Yoo *et al.* and Blitzblau *et al.* performed a dose escalation trial, testing up to 21 Gy in a single fraction in an additional 32 patients (26,27). They required the use of prone MRI and prone CT for planning, using the biopsy clip as a fiducial for daily cone beam CT verification of treatment setup. The study authors emphasized the

importance of having MRI for planning as CTs were found to be insufficient for visualizing tumors and/or underestimated tumor sizes. These authors also pointed out the importance of being able to administer this using EBRT. In contrast to brachytherapy or IORT, EBRT does not require specialized equipment and comparably, less operator dependent expertise, thus making it more widely available to patients.

The conclusion from the above studies in the context of more extensive data with PAPBI is that while advanced treatment planning and delivery (i.e., IMRT or availability of MRI simulation) is not always required, they offer increased target precision. This reduces the margin expansion needed for treatment set up variation and therefore, may improve cosmesis and reduce risk of toxicity. Furthermore, the advent of new image-guided radiotherapy (IGRT) technologies incorporating intra-fractional IGRT and magnetic resonance-based linear accelerators (MR-LINACS) has the potential to even further improve the accuracy and precision of treatment planning.

### **Application of modern IGRT and novel treatment modalities to PAPBI**

Another form of IGRT incorporates intrafractional, fiducial tracking using the Cyberknife (Accuray, Palo Alto CA). Most of the experience with using Cyberknife and fiducial tracking for PBI has been in the postoperative setting (28). Initial reports were made in 2011 by the Swedish Medical Center in Seattle and Winthrop University Hospital of a combined analysis of 47 patients treated with either 10 fractions twice daily (BID) or 5 fractions daily to a dose of 25–36 Gy (29). In this particular study, as a part of treatment planning for APBI, gold fiducial markers were placed at the time of surgery or post-operatively by radiation oncologists. The target CTV included a minimally 2 mm PTV expansion. Additional work at University of Texas South Western (UTSW) reported the outcomes of 75 patients treated from 2010–2015 utilizing gold fiducials and synchrony real time tracking. In this case, no CTV to PTV margin was used so CTV = PTV (10). In both analyses, cosmesis was excellent.

Dosimetrically, using Cyberknife as opposed to 3D EBRT appears to result in a significantly lower dose to the organs at risk while maintaining conformal target coverage, as reported by comparative studies by UTSW and Fox Chase Medical Center (30,31). Implementing the use of Cyberknife fiducial tracking may be more challenging logistically with PAPBI, as fiducials would not be available.

However, there is likely an opportunity for collaboration with diagnostic radiology so that fiducials could be placed at the time of US-guided biopsy or in a subsequent encounter, similar to the process currently being utilized for fiducial tracking in patients with prostate cancer. Alternatively, as has been done by the Swedish Medical Center/Winthrop Study, the treating radiation oncologist could also place these fiducials at the time of CT simulation. As noted above, there is potentially less margin for error when localizing to = fiducials placed in the tumor mass as compared to fiducials placed in the healing postoperative cavity at the time of or after surgery, as there may be movement of the fiducial markers in the tumor bed/cavity during wound healing.

In addition to Cyberknife, newer advanced image guidance technologies are being investigated. The Gammapod, currently being tested at the University of Maryland, is similar in concept to the Gammaknife and uses Cobalt-60 (32). The patients are loaded onto the “pod” in a standing position and are then transitioned into a prone position with a vacuum assisted breast cup that can interlock into the couch and maintain the position of the breast once the patient is prone. The patient can then be imaged using a CT or MRI simulator with the breast cup in place in a separate location. Then, the patient can be returned to the unit for treatment. Another technology that is being developed is a stereotactic unit called the Mammoknife which is a self-shielded device dedicated to the treatment of patients with breast cancer, shielding the rest of the patient’s body to scatter radiation exposure. A prototype has been available since 2010, but it is pending final FDA testing and approval with likely implementation in the next few years (15).

### **Molecular and correlative studies**

An added value of PAPBI therapy is that it can theoretically provide an opportunity to assess treatment response. Tissue sampling before radiation can provide an opportunity to identify biomarkers that prognosticate patient outcomes akin to that already used to assess for decisions regarding pre-operative chemotherapy. A response assessment after pre-operative RT would also offer an opportunity to guide the use of adjuvant therapy. In addition, this allows for tissue sampling that can be used for biomarker studies of radiation response. Such studies have the potential to guide the development of future predictive or prognostic biomarkers and shed light on the biology of how breast cancer cells respond to radiation. For example, Horton *et al.* showed that Luminal subtype cells derived from patients

following PAPBI at the time of lumpectomy showed a much higher gene expression response profile to radiation than Her2+ or basal cell types (20). They postulated that PAPBI may complement the use of neoadjuvant chemotherapy since the opposite is typically observed.

Another notable PAPBI study is that by Nichols *et al.*, who reported on the use of fractionated SBRT delivered to a dose of 38.5 Gy in 3.85 Gy twice daily fractions at least 3 weeks prior to lumpectomy. Importantly, they were able to report findings from the H&E samples of the patients' surgical specimen. The rates of pathologic complete response (pCR) observed was observed in 4 out of the 27 treated patients. No local failures were reported after 3 years of follow up (19). The interpretation of the low percentage of pCR patients is limited by the short delay between RT and lumpectomy. Given that it is well-established that radiation-mediated cell death is a late process that occurs over weeks to months, it is certainly possible that with longer time between RT and surgery, a greater rate of pCR would be observed.

The role of PAPBI in affecting tumor response is being better addressed in more modern studies including one Canadian pilot study by Tiberi *et al.* They observed a good pathological response in 8/10 study participants with median of 3% residual cellularity and pCR of 50% (8). Indeed a recent trial from the Netherlands (ABLATIVE), which is a single-arm prospective study of 36 patients who underwent single fraction PAPBI (15 Gy to CTV and 20 Gy to GTV) 6–8 months prior to lumpectomy, showed a promising rate of 42% of both pCR and radiographic complete response (67% with both) (9). More advanced genomics and molecular immunology studies of tumors after PAPBI have not yet been reported, but would add important knowledge to the literature regarding differential tumor response to radiation therapy and potentially identify new molecular biomarkers to guide clinical management.

### Future directions and considerations

Perhaps a radical proposal, but there is a possibility here for the investigation of how PAPBI can play a role either in conjunction with, complementary to or in lieu of pre-operative systemic or endocrine therapy for patients with early stage hormone receptor (HR) positive breast cancer. For example, it is well-established that patients with HR positive disease are less likely to respond to pre-operative chemotherapy. Thus, for these patients, pre-

operative RT may be a good alternative. Additionally, PAPBI has some potential advantages when compared to neoadjuvant chemotherapy. Comparatively, pre-operative RT is likely faster, more convenient, and less morbid. Most importantly, in nearly all patients with early stage breast cancer regardless of whether systemic therapy would be recommended, RT remains a central component of breast conservation and significantly reduces local-regional recurrence on the order of two-thirds.

Finally, PAPBI can lead to pathologic downstaging, and thereby potentially reduce the overuse of systemic therapy, which can be morbid or associated with late toxicities. In patients with a dramatic response to RT, chemotherapy may no longer be recommended after definitive surgery for some patients, even though they may have been recommended chemotherapy based on pre-operative staging.

Finally, some have raised the idea of being able to use non-invasive biomarkers in conjunction with imaging to potentially select candidates who may be able to avoid lumpectomy after pre-operative therapy. It is certainly possible that adding PAPBI to pre-operative systemic therapy may further improve the rates of pCR such that there may a possibility of avoiding surgery in certain carefully-selected patient populations. There are certainly good precedents for this paradigm in other solid malignancies where neoadjuvant chemoradiation was a part of a standard of care paradigm that required surgical resection but over time chemoradiation became the primary modality of management patients. This includes anal cancer, locally advanced cervical cancer or larynx cancer, small intracranial metastases, and now is an evolving consideration for low-lying rectal cancers. Whether or not a pCR can be observed in a substantial proportion of breast cancer patients and whether biomarkers could be prognostic of pCR rates remain to be seen. In the meantime, these are certainly provocative concepts awaiting future investigation.

### Conclusions

In summary, PAPBI is an innovative approach to the delivery of radiation therapy as a part of breast conservation for patients with early stage breast cancer. As has been shown more extensively in the post-operative setting, PAPBI appears to be safe and has a number of advantages as compared to APBI currently being practiced across the US. This includes smaller treatment volumes, more accurate image guidance, resection of high-dose treatment

area, ability to have pre- and post-RT tissue for response assessment and a possible de-escalation of systemic therapy and reduced surgical volume. While promising, significant work remains to be done in carrying out prospective, randomized, Phase III clinical trials with longitudinal safety and efficacy data comparing PABPI to standard WBRT or post-operative APBI.

### Acknowledgments

*Funding:* Dr. Li is a recipient of the NIH NCI F32 Individual post-doctoral fellowship. Dr. Barry and Dr. Li received the ACRO new practitioner grant to evaluate barrier to promotion and partnership for women in radiation oncology. Dr. Barry serves as an El-Sevier Pathways consultant. She used to serve as an Osler Board review course instructor.

### Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Annals of Breast Surgery* for the series “Advancements and Opportunities for Breast Irradiation”. The article has undergone external peer review.

*Conflicts of Interest:* Both authors have completed the ICMJE uniform disclosure form (available at <https://abs.amegroupp.com/article/view/10.21037/abs-20-133/coif>). The series “Advancements and Opportunities for Breast Irradiation” was commissioned by the editorial office without any funding or sponsorship. PNB served as the unpaid Guest Editor of the series. YRL is supported by the NIH F32 Fellowship award. PNB has received the ACRO new practitioner grant evaluating barriers to promotion for women in radiation oncology. She serves as the El-Sevier Breast Pathway Chair and El-Sevier Pathways consultant. She has provided teaching and received honorariums for the following: Osler board review course on Breast Cancer; Multiple lectures given or moderated for breast cancer with SANTRO, ACRO, RUSH, ROPH, Franciscan Health in Munster, IN, Chicago Radiological Society, American Brachytherapy society. She has received travel support for serving as the Scientific Program Co-Chair for ACRO; ASTRO faculty. She participates in UPMC Radiation Oncology Data Safety Committee. She is a board member of ACRO and she serves as a Guideline writing committee member for Breast Reconstruction After Mastectomy. Other financial and non-financial interests include: she has served

as Moderator of multiple ACRO breast sessions; NRG concept presentation on preoperative radiation for breast cancer; Guest editor of *Annals of Breast Surgery Radiation Focused issue*; ABR volunteer; NRG Oncology breast committee and rare tumor member; ASCO Hereditary Breast Cancer Guideline Consensus Panel Member. The authors have no other conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

### References

1. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. *Pract Radiat Oncol* 2018;8:145-52.
2. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med* 2010;362:513-20.
3. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol* 2013;14:1086-94.
4. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. *Eur J Cancer* 2015;51:451-63.
5. Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast

- cancer (RAPID): a randomised controlled trial. *Lancet* 2019;394:2165-72.
6. Berrang TS, Olivotto I, Kim DH, et al. Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. *Int J Radiat Oncol Biol Phys* 2011;81:1220-7.
  7. Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. *Lancet* 2019;394:2155-64.
  8. Tiberi D, Vavassis P, Nguyen D, et al. Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer. *Curr Oncol* 2020;27:155-8.
  9. Vasmel JE, Charaghvandi RK, Houweling AC, et al. Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation. *Int J Radiat Oncol Biol Phys* 2020;106:821-9.
  10. Rahimi A, Thomas K, Spangler A, et al. Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation. *Int J Radiat Oncol Biol Phys* 2017;98:196-205.e2.
  11. Vicini FA, Goldstein NS, Pass H, et al. Use of pathologic factors to assist in establishing adequacy of excision before radiotherapy in patients treated with breast-conserving therapy. *Int J Radiat Oncol Biol Phys* 2004;60:86-94.
  12. Rabinovitch R, Moughan J, Vicini F, et al. Long-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma. *Int J Radiat Oncol Biol Phys* 2016;96:1054-9.
  13. Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. *Int J Radiat Oncol Biol Phys* 2009;75:1290-6.
  14. Meattini I, Marrazzo L, Saieva C, et al. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. *J Clin Oncol* 2020;38:4175-83.
  15. Rahimi A, Timmerman R. New Techniques for Irradiating Early Stage Breast Cancer: Stereotactic Partial Breast Irradiation. *Semin Radiat Oncol* 2017;27:279-88.
  16. Semiglazov VF, Topuzov EE, Bavli JL, et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. *Ann Oncol* 1994;5:591-5.
  17. Bollet MA, Sigal-Zafrani B, Gambotti L, et al. Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. *Eur J Cancer* 2006;42:2286-95.
  18. Skinner KA, Dunnington G, Silberman H, et al. Preoperative 5-fluorouracil and radiation therapy for locally advanced breast cancer. *Am J Surg* 1997;174:705-7; discussion 707-8.
  19. Nichols E, Kesmodel SB, Bellavance E, et al. Preoperative Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Preliminary Results of a Prospective, Phase 2 Trial. *Int J Radiat Oncol Biol Phys* 2017;97:747-53.
  20. Horton JK, Blitzblau RC, Yoo S, et al. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. *Int J Radiat Oncol Biol Phys* 2015;92:846-55.
  21. van der Leij F, Bosma SC, van de Vijver MJ, et al. First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. *Radiother Oncol* 2015;114:322-7.
  22. Yang TJ, Tao R, Elkhuzen PH, et al. Tumor bed delineation for external beam accelerated partial breast irradiation: a systematic review. *Radiother Oncol* 2013;108:181-9.
  23. Kaufman CS. Increasing Role of Oncoplastic Surgery for Breast Cancer. *Curr Oncol Rep* 2019;21:111.
  24. Shah C, Al-Hilli Z, Schwarz G. Oncoplastic Surgery in Breast Cancer: Don't Forget the Boost! *Ann Surg Oncol* 2018;25:2509-11.
  25. Yeboa DN, Xu X, Jones BA, et al. Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004-2009. *Am J Clin Oncol* 2016;39:568-74.
  26. Yoo S, Blitzblau R, Yin FF, et al. Dosimetric comparison of preoperative single-fraction partial breast radiotherapy techniques: 3D CRT, noncoplanar IMRT, coplanar IMRT, and VMAT. *J Appl Clin Med Phys* 2015;16:5126.
  27. Blitzblau RC, Arya R, Yoo S, et al. A phase 1 trial of preoperative partial breast radiation therapy: Patient selection, target delineation, and dose delivery. *Pract Radiat Oncol* 2015;5:e513-20.
  28. Obayomi-Davies O, Kole TP, Oppong B, et al. Stereotactic Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Rationale, Feasibility, and Early Experience



- Using the CyberKnife Radiosurgery Delivery Platform. *Front Oncol* 2016;6:129.
29. Vermuelen S, Murphy KT, Giap H. Back to the future: radiosurgery in the new frontier. *Transl Cancer Res* 2014;3:293-4.
30. Heinzerling JH, Ding C, Ramirez E, et al. Comparative Dose-Volume Analysis for CyberKnife and 3D Conformal Partial Breast Irradiation Treatment of Early Stage Breast Cancer. *Int J Radiat Oncol Biol Phys*, 2010. doi: 10.1016/j.ijrobp.2010.07.1911.
31. Fan J, Hayes S, Freedman G, et al. Planning the Breast Boost: Dosimetric Comparison of CyberKnife, Photon Mini Tangents, IMRT, and Electron Techniques. *Int J Radiat Oncol* 2010;78:S788-9.
32. Yu CX, Shao X, Zhang J, et al. GammaPod-a new device dedicated for stereotactic radiotherapy of breast cancer. *Med Phys* 2013;40:051703.

doi: 10.21037/abs-20-133

**Cite this article as:** Li YR, Barry PN. Pre-operative partial breast irradiation: revolutionizing radiation treatment for women with early stage breast cancer. *Ann Breast Surg* 2022;6:38.